← ConditionsAutoimmune & chronic complex illness

Long-COVID / post-viral

The one rigorously-trialed peptide (aviptadil) failed; prioritize plausibility + safety.

Decision support, not prescription. You decide.

Primary: Immune & Inflammation ModulationSecondary: Cellular Energy, Mito & LongevitySecondary: Cognitive, Mood & NeuroSummary grade: emerging
!

WarningBPC-157 crash risk in post-viral/ME-CFS

Post-viral/ME-CFS patients report crashing at standard dose; microdose 10–25%.

Candidate agents

3 agents · ranked by role, then evidence
Thymosin Alpha-1peptide · headlineLead503A compounded
Evidence · PubMed
Emerging

Best rationale but conflicting human data (mortality benefit in acute COVID; harm signal in a cohort).

PMID 37845598
Community · Reddit
Positive

8 reports · Strongest LC reports: fatigue/brain-fog resolution; effect lasts 48-72h

Peers · your network
No peer data yet
VIPpeptide · headlineResearch use only
Evidence · PubMed
None

Aviptadil (VIP) FAILED primary endpoints in acute COVID (TESICO); never trialed for long-COVID.

PMID 37348524
Community · Reddit
No community reports
Peers · your network
No peer data yet
BPC-157peptide · headline503A · PCAC-pending

Warning BPC-157 crash risk in post-viral/ME-CFS

Evidence · PubMed
No evidence rows
Community · Reddit
Mixed

4 reports · ~10% baseline lift; crash risk in severe ME/CFS

Peers · your network
No peer data yet

Matching protocol templates

Browse all →

The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.